A detailed history of California State Teachers Retirement System transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, California State Teachers Retirement System holds 122,437 shares of CERE stock, worth $5.05 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
122,437
Previous 74,690 63.93%
Holding current value
$5.05 Million
Previous $3.17 Million 63.46%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$40.88 - $43.27 $1.95 Million - $2.07 Million
47,747 Added 63.93%
122,437 $5.18 Million
Q4 2023

Feb 13, 2024

BUY
$20.27 - $42.44 $113,532 - $237,706
5,601 Added 8.11%
74,690 $3.17 Million
Q3 2023

Nov 14, 2023

SELL
$20.26 - $31.91 $134,425 - $211,722
-6,635 Reduced 8.76%
69,089 $1.51 Million
Q2 2023

Aug 21, 2023

SELL
$23.9 - $35.38 $12,475 - $18,468
-522 Reduced 0.68%
75,724 $2.41 Million
Q1 2023

May 09, 2023

SELL
$22.82 - $35.32 $19,100 - $29,562
-837 Reduced 1.09%
76,246 $1.86 Million
Q4 2022

Feb 14, 2023

BUY
$25.35 - $31.96 $116,204 - $146,504
4,584 Added 6.32%
77,083 $2.43 Million
Q3 2022

Nov 18, 2022

SELL
$25.5 - $41.42 $25,474 - $41,378
-999 Reduced 1.36%
72,499 $2.05 Million
Q2 2022

Aug 15, 2022

BUY
$20.62 - $37.15 $374,273 - $674,309
18,151 Added 32.79%
73,498 $1.94 Million
Q1 2022

May 16, 2022

SELL
$23.5 - $35.38 $85,822 - $129,207
-3,652 Reduced 6.19%
55,347 $1.94 Million
Q4 2021

Feb 15, 2022

BUY
$29.21 - $44.64 $73,579 - $112,448
2,519 Added 4.46%
58,999 $1.91 Million
Q3 2021

Nov 15, 2021

BUY
$21.26 - $38.85 $166,805 - $304,817
7,846 Added 16.13%
56,480 $1.67 Million
Q2 2021

Aug 16, 2021

BUY
$12.56 - $29.69 $610,843 - $1.44 Million
48,634 New
48,634 $1.25 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Market Cap $6.42B
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.